Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study assessing the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104, a first-in-class bifunctional biologic. The drug will be evaluated as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) in China.<\/p>\n\n\n\n
PNH: Disease Overview and Treatment Landscape<\/strong>
PNH is a rare, life-threatening blood disease characterized by the production of aberrant red blood cells that are recognized as foreign entities within the body, leading to hyperactivation of the complement system and destruction of red blood cells. Patients with PNH may experience anemia, blood clots, and impairments to bone marrow function. Current treatments for PNH target single complement proteins and have shown reductions in hemolysis. However, recent studies suggest that treatments inhibiting both the alternative and terminal complement pathways may offer further improvements in patient outcomes.<\/p>\n\n\n\n